Cargando…

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mateos, María-Victoria, Bladé, Joan, Bringhen, Sara, Ocio, Enrique M, Efebera, Yvonne, Pour, Luděk, Gay, Francesca, Sonneveld, Pieter, Gullbo, Joachim, Richardson, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601491/ https://www.ncbi.nlm.nih.gov/pubmed/32992506 http://dx.doi.org/10.3390/jcm9103120

Ejemplares similares

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016)

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
por: Bringhen, Sara, et al.
Publicado: (2021)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
por: Larocca, Alessandra, et al.
Publicado: (2021)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
por: Schjesvold, F, et al.
Publicado: (2023)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
por: Ocio, Enrique M., et al.
Publicado: (2023)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
por: Gebraad, Arjen, et al.
Publicado: (2022)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
por: Mateos, M, et al.
Publicado: (2023)

Role of Stem Cell Transplantation in Multiple Myeloma
por: Devarakonda, Srinivas, et al.
Publicado: (2021)

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
por: Miettinen, Juho, et al.
Publicado: (2023)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
por: Fernández de Larrea, Carlos, et al.
Publicado: (2021)

The DAC system and associations with multiple myeloma
por: Ocio, Enrique M., et al.
Publicado: (2010)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
por: Smetana, Jan, et al.
Publicado: (2018)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
por: Buda, Gabriele, et al.
Publicado: (2010)

Insights on Multiple Myeloma Treatment Strategies
por: Mateos, María-Victoria, et al.
Publicado: (2018)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
por: Ocio, Enrique M., et al.
Publicado: (2023)

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
por: Knight, Andrea, et al.
Publicado: (2021)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sp40vpcklq5c3lhe41easkm8m